By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Regenerative Precision Medicine for Chronic Inflammation

First Focus
More CIDs

Integrating medical power and biological precision by generative AI

The unsolved challenge of future medicine is either chronic inflammatory disease (CID) or tumor. Two-thirds of this challenge consists of chronic inflammation. Thus far, biomarker- and AI-driven development has just empowered tumor treatment. None of this has been available for chronic inflammatory disease.
Until now. There is now a solution. We have it.

Translational Research for Regenerative Medicine

Precision medicine for Chronic Inflammation

Transgenion, a Spin-off of the Medical University of Vienna, is a pharmaceutical Research and Development Company established in 2015 based on the unprecedented success of more than twenty years of translational research by Prof. Rolf Ziesche and his team in Vienna, supported by both national and EU funding.

Transgenion realizes groundbreaking individualized diagnosis and treatment for chronic inflammatory diseases (including COPD and IPF), a very large group of diseases in people aged 50 years or more accounting for 70 percent of all diseases at that age.

20 Bio.

global market revenues just for treatment of COPD

30,4 Bio.

forecast for 2031

The Transgenion Advantage

Currently at Technical Readiness Level 6

Technology demonstrated in relevant environment
Successful Clinical Pilot Study

Complete analysis for all clinically relevant markers in lung tissue based on 3-year observation per subject, representing COPD progression over more than 30 years.

Sequential Recording

First-time sequential recording of all relevant markers throughout the entire COPD course (from the risk stage to end-stage).

Unique Dataset

Unique dataset fully patented (25 patents across US, Europe and Japan).

>10 Years Market Lead

In summary, this results in a market lead of at least 10 years.


The perfect Blend of Strategic Vision and Practical Execution

"Transgenion will bridge the challenging gap between applied clinical sciences and pharmaceutical industry to establish regenerative precision medicine for the world’s aging societies."

Prof. Dr. Rolf Ziesche

Inventor, Founder & CEO
at Transgenion

Upcoming Events


22nd Lung Science Conference 2024
The ERS Lung Science Conference is at the forefront of basic and translational respiratory science and is an essential event for budding respiratory researchers.
Estoril, Portugal


World Respiratory Medicine Congress 2024
Three-day event bringing together experts in pulmonology and respiratory medicine for robust discussions on advancements and strategies in the field.
Barcelona, Spain


34th European Respiratory Society (ERS)
The European Respiratory Society Congress is an annual event that brings together the world’s respiratory experts to showcase all the latest advances in respiratory medicine and science.
Vienna, Austria


ESMO Congress 2024
The ESMO Congress is a globally influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.
Barcelona, Spain

Explore how Transgenion is leading a groundbreaking transformation in the battle against COPD and various respiratory conditions.

Chronic Obstructive Pulmonary Disease (COPD)

COPD) is a progressive and debilitating respiratory condition characterized by persistent airflow limitation. This article provides a comprehensive review of COPD, including its description, pathology, epidemiology, and treatment strategies.

Overview of the socioeconomic burden imposed by COPD

The socioeconomic impact of Chronic Obstructive Pulmonary Disease (COPD) is substantial, affecting individuals, families, and healthcare systems worldwide. COPD imposes both direct and indirect costs, encompassing medical expenses, lost productivity, and diminished quality of life.

Inventor of the Year 2016 by Medical University of Vienna

Rolf Ziesche from the Clinical Department of Pulmonology at the University Clinic for Internal Medicine II of the Medical University of Vienna was elected 'Inventor of the Year 2016' by the Medical University of Vienna.

Unique Investment Opportunity

The future of Personalized Medicine for healthy aging has started. Seize this unprecedented opportunity to be a pioneer in the Personalized Medicine movement!

Get in Touch!

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.